Rashmika Patel

1.3k total citations
14 papers, 404 citations indexed

About

Rashmika Patel is a scholar working on Oncology, Immunology and Electrical and Electronic Engineering. According to data from OpenAlex, Rashmika Patel has authored 14 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Immunology and 2 papers in Electrical and Electronic Engineering. Recurrent topics in Rashmika Patel's work include CAR-T cell therapy research (10 papers), Immunotherapy and Immune Responses (2 papers) and Integrated Circuits and Semiconductor Failure Analysis (2 papers). Rashmika Patel is often cited by papers focused on CAR-T cell therapy research (10 papers), Immunotherapy and Immune Responses (2 papers) and Integrated Circuits and Semiconductor Failure Analysis (2 papers). Rashmika Patel collaborates with scholars based in United States, India and United Kingdom. Rashmika Patel's co-authors include James N. Kochenderfer, Jennifer N. Brudno, Lekha Mikkilineni, David F. Stroncek, Norris Lam, Ronald E. Gress, Jeremy J. Rose, Danielle Vanasse, Brenna Hansen and Andrew J. Wardlaw and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Rashmika Patel

14 papers receiving 401 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rashmika Patel United States 8 339 134 120 118 77 14 404
Sophia Stock Germany 9 337 1.0× 146 1.1× 110 0.9× 121 1.0× 97 1.3× 16 383
Marika Sherman United States 6 397 1.2× 111 0.8× 79 0.7× 102 0.9× 87 1.1× 12 420
Ruimin Hong China 9 283 0.8× 127 0.9× 60 0.5× 75 0.6× 72 0.9× 29 355
Edward Waldron United States 5 291 0.9× 160 1.2× 64 0.5× 63 0.5× 73 0.9× 13 362
Elizabeth Halton United States 14 555 1.6× 117 0.9× 141 1.2× 129 1.1× 187 2.4× 29 604
Paul Castillo United States 9 331 1.0× 130 1.0× 130 1.1× 154 1.3× 100 1.3× 34 462
Xiaoqian Liang China 6 243 0.7× 117 0.9× 54 0.5× 98 0.8× 68 0.9× 8 334
Danielle Vanasse United States 6 507 1.5× 189 1.4× 158 1.3× 135 1.1× 142 1.8× 7 549
Claudia Diamonte United States 10 322 0.9× 73 0.5× 84 0.7× 79 0.7× 108 1.4× 18 353
Jiazhen Cui China 11 312 0.9× 139 1.0× 79 0.7× 118 1.0× 76 1.0× 39 423

Countries citing papers authored by Rashmika Patel

Since Specialization
Citations

This map shows the geographic impact of Rashmika Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rashmika Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rashmika Patel more than expected).

Fields of papers citing papers by Rashmika Patel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rashmika Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rashmika Patel. The network helps show where Rashmika Patel may publish in the future.

Co-authorship network of co-authors of Rashmika Patel

This figure shows the co-authorship network connecting the top 25 collaborators of Rashmika Patel. A scholar is included among the top collaborators of Rashmika Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rashmika Patel. Rashmika Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Rivero, Jaydira Del, John Glod, Kimberlea Cooper, et al.. (2025). A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumors and carcinomas.. Journal of Clinical Oncology. 43(4_suppl). 1 indexed citations
2.
Brudno, Jennifer N., Nisha Patel, Roberto Maass‐Moreno, et al.. (2023). Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. Blood Advances. 8(3). 802–814. 12 indexed citations
3.
Brudno, Jennifer N., Nisha Patel, Lekha Mikkilineni, et al.. (2022). Transient Responses and Significant Toxicities Due to Cytopenias and Rashes with Anti-CD30 CAR T Cells for CD30-Expressing Lymphomas: Results of a Phase I Clinical Trial. Blood. 140(Supplement 1). 12731–12732. 2 indexed citations
4.
Mikkilineni, Lekha, Elisabet E. Manasanch, Katherine A. Weissler, et al.. (2022). T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma. Blood. 140(Supplement 1). 7433–7434. 6 indexed citations
5.
Mikkilineni, Lekha, Elisabet E. Manasanch, Jennifer N. Brudno, et al.. (2021). Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity. Blood. 138(Supplement 1). 3837–3837. 8 indexed citations
6.
Brudno, Jennifer N., Norris Lam, Danielle Vanasse, et al.. (2020). Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nature Medicine. 26(2). 270–280. 228 indexed citations
7.
8.
9.
Brudno, Jennifer N., Norris Lam, David F. Stroncek, et al.. (2018). Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR. Blood. 132(Supplement 1). 697–697. 8 indexed citations
10.
Patel, Rashmika, et al.. (2018). Estimate Hyoscine Butylbromide and Mefenamic Acid by RP-HPLC Method Development and Accelerated Stability Study in Pure and Combine Dosage Form. Eurasian Journal of Analytical Chemistry. 13(4). 3 indexed citations
11.
Brudno, Jennifer N., Stefania Pittaluga, David F. Stroncek, et al.. (2018). Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions.. Journal of Clinical Oncology. 36(15_suppl). 3052–3052. 7 indexed citations
12.
Brudno, Jennifer N., Victoria Shi, David Stroncek, et al.. (2016). T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial. Blood. 128(22). 999–999. 27 indexed citations
13.
Patel, Rashmika, et al.. (2014). Okra mucilage act as a potential binder for the preparation of tablet formulation. Der pharmacia lettre. 6(3). 31–39. 5 indexed citations
14.
Patel, Rashmika, et al.. (2009). THE CHEMOKINE CXCL16 IS HIGHLY AND CONSTITUTIVELY EXPRESSED BY HUMAN BRONCHIAL EPITHELIAL CELLS. Experimental Lung Research. 35(4). 272–283. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sophia Stock Breakdown of academic impact, for papers by Marika Sherman Breakdown of academic impact, for papers by Ruimin Hong Breakdown of academic impact, for papers by Edward Waldron Breakdown of academic impact, for papers by Elizabeth Halton Breakdown of academic impact, for papers by Paul Castillo Breakdown of academic impact, for papers by Xiaoqian Liang Breakdown of academic impact, for papers by Danielle Vanasse Breakdown of academic impact, for papers by Claudia Diamonte Breakdown of academic impact, for papers by Jiazhen Cui
Rankless by CCL
2026